8-K: Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Acute Stress Reaction

Tonix Pharmaceuticals has initiated a Phase 2 trial to assess TNX-102 SL for reducing acute stress reaction and acute stress disorder, supported by a $3 million grant from the U.S. Department of Defense.

Summary

• Tonix Pharmaceuticals announced the first patient has been dosed in a Phase 2 investigator-initiated OASIS trial.
• The OASIS trial is evaluating TNX-102 SL for reducing the severity of acute stress reaction (ASR) and the frequency of acute stress disorder (ASD).
• The trial is sponsored by the University of North Carolina (UNC) Institute for Trauma Recovery and supported by a $3 million grant from the U.S. Department of Defense (DoD).
• The OASIS trial will examine the safety and efficacy of TNX-102 SL in patients presenting to the emergency department (ED) after a motor vehicle collision (MVC).
• Approximately 180 MVC-trauma survivors will be enrolled at ED study sites across the U.S.
• Participants will be randomized to receive either TNX-102 SL 5.6 mg or a placebo over a two-week course.
• Topline results from the trial are expected in the second half of 2026.
• TNX-102 SL is a centrally acting, non-opioid investigational drug designed for chronic use.
• Tonix has submitted an NDA for TNX-102 SL for the management of fibromyalgia, with a PDUFA goal date of August 15, 2025.
• Tonix also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the advancement of a clinical trial and the support from a government grant. However, the inherent risks associated with pharmaceutical development temper the overall sentiment.

Positives

• The initiation of the Phase 2 OASIS trial represents progress in the development of TNX-102 SL for treating acute stress reaction and acute stress disorder.
• The $3 million grant from the U.S. Department of Defense provides financial support for the trial.
• TNX-102 SL has shown potential in improving sleep quality in PTSD and has suggested activity on sleep and stress-related symptoms in previous trials.
• The company has a PDUFA goal date of August 15, 2025, for TNX-102 SL for fibromyalgia.

Risks

• The forward-looking statements in the report are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include the failure to obtain FDA clearances or approvals, the failure to successfully market products, and the uncertainties of patent protection and litigation.
• The development of new pharmaceutical products carries significant risks related to clinical development, regulatory approval, and commercialization.

Future Outlook

Tonix anticipates topline results from the OASIS trial in the second half of 2026 and is awaiting a decision on marketing authorization for TNX-102 SL for fibromyalgia with a PDUFA goal date of August 15, 2025.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that TNX-102 SL has been shown to improve sleep quality in PTSD.
• He also mentioned that previous trials of TNX-102 SL suggested activity on sleep and stress-related symptoms in the first several weeks of treatment.
• He emphasized the significant unmet need for treating ASR after traumatic events and expressed encouragement from the support of TNX-102 SL's prior data improving PTSD symptomatology.

Industry Context

This announcement is relevant to the broader pharmaceutical industry, particularly in the areas of mental health and trauma treatment. The development of TNX-102 SL for acute stress reaction and acute stress disorder addresses a significant unmet need in both civilian and military populations.

Comparison to Industry Standards

• The AURORA initiative, with its $40 million funding, is a major national research initiative, suggesting that the OASIS trial is part of a larger effort to improve the understanding, prevention, and recovery of individuals who experience traumatic events.
• The trial's focus on motor vehicle collision (MVC) trauma survivors aligns with the high prevalence of trauma-related emergency department visits in the U.S.
• The development of TNX-102 SL as a non-opioid treatment option is consistent with the industry's focus on addressing the opioid crisis and finding alternative pain management solutions.

Stakeholder Impact

• Positive impact on patients suffering from acute stress reaction and acute stress disorder if TNX-102 SL proves effective.
• Potential benefit to shareholders through the advancement of the company's drug development pipeline.
• Contribution to the medical community's understanding and treatment of trauma-related conditions.

Next Steps

• Enrollment and randomization of approximately 180 MVC-trauma survivors in the OASIS trial.
• Administration of TNX-102 SL 5.6 mg or placebo over a two-week course to trial participants.
• Collection and analysis of data to assess the safety and efficacy of TNX-102 SL.
• Anticipation of topline results from the OASIS trial in the second half of 2026.
• FDA decision on marketing authorization for TNX-102 SL for fibromyalgia by August 15, 2025.

Key Dates

Keywords

TNX-102 SL, OASIS Trial, Acute Stress Reaction, Acute Stress Disorder, Tonix Pharmaceuticals, Clinical Trial, PTSD, Fibromyalgia, Emergency Department, Motor Vehicle Collision